RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug duo shows promise against tough head and neck cancers
Disease control OngoingThis study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control OngoingThis study tested a combination of three drugs (sorafenib, carboplatin, and paclitaxel) in 48 adults with head and neck squamous cell cancer that had spread or returned. The goal was to see how well the treatment shrank tumors and delayed cancer growth. Participants received the …
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
Promising combo targets Hard-to-Treat head and neck cancer
Disease control OngoingThis study tests a combination of an immunotherapy drug (cemiplimab) and two low-dose chemotherapy drugs (paclitaxel and carboplatin) in people with head and neck cancer that has returned or spread. The goal is to see if this mix can shrink tumors better than standard treatments.…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC